• PQ3 A DECISION TREE APPROACH TO ESTIMATING COST SAVINGS OF PAY FOR PERFORMANCE PROGRAMS IN A PPO SETTING

    May 1, 2007, 00:00

  • PIN39 CULTURAL ADAPTATION AND VALIDATION OF A HEALTHRELATED QUALITY OF LIFE QUESTIONNAIRE (HRQOL) FOR ENGLISH-SPEAKING HEPATITIS B PATIENTS IN SINGAPORE

    May 1, 2007, 00:00

  • PCV9 ISOLATED SYSTOLIC HYPERTENSION IN A COHORT OF INNER CITY MINORITY PATIENTS

    May 1, 2007, 00:00

  • PEY2 PREVALENCE OF GLAUCOMATOUS RISK FACTORS IN PATIENTS FROM A MANAGED-CARE SETTING- A PILOT EVALUATION

    May 1, 2007, 00:00

  • PCN39 GAP BETWEEN INPATIENT TREATMENT COST OF AND MORTALITY DUE TO BREAST CANCER IN HUNGARY

    May 1, 2007, 00:00

  • PGI3 CONSTIPATION IN PERSONS RECEIVING HOSPICE CARE- PRELIMINARY ESTIMATES

    May 1, 2007, 00:00

  • PMH48 PREFERENCE AND WILLINGNESS-TO-PAY STUDY TO ASSESS THE VALUE OF ATOMOXETINE USING DISCRETE CHOICE ANALYSIS- UK PARENTS PERSPECTIVE

    May 1, 2007, 00:00

  • PCV49 DEVELOPMENT OF AN INTERACTIVE MODEL TO PREDICT LOW DENSITY LIPOPROTEIN CHOLESTEROL (LDL) REDUCTION AND LDL GOAL ATTAINMENT ASSOCIATED WITH STATIN USE IN ROUTINE CLINICAL PRACTICE

    May 1, 2007, 00:00

  • PRS9 ESTIMATED COST SAVINGS ASSOCIATED WITH THE USE OF A NEW TASTE-MASKED ORAL CLARITHROMYCIN PREPARATION FOR THE TREATMENT OF RESPIRATORY TRACT INFECTIONS IN CHILDREN IN GERMANY

    May 1, 2007, 00:00

  • OB2 THE COST OF THE METABOLIC SYNDROME IN THE ELDERLY- FINDINGS FROM THE CARDIOVASCULAR HEALTH STUDY

    May 1, 2007, 00:00

  • PCN26 FIRST-, SECOND- AND THIRD-LINE CHEMOTHERAPY FOR NONSMALL CELL LUNG CANCER- PATTERNS OF CARE AND COST

    May 1, 2007, 00:00

  • PCV37 THE IMPACT OF CARE GAP IN MANAGING HIGH CARDIOVASCULAR RISK PATIENTS-A CANADIAN POPULATION ANALYSIS

    May 1, 2007, 00:00

  • PND19 DEVELOPING A MIGRAINE QUALITY OF CARE MEASUREMENT SET

    May 1, 2007, 00:00

  • PAA18 DATA EXTRACTION METHODS, ECONOMETRIC MODELING AND FACTORIAL ANALYSIS REVEAL CLINICALLY IMPORTANT PATIENT PROFILES IN CHRONIC ASTHMA

    May 1, 2007, 00:00

  • A Cost-Effectiveness Decision Model for Antiepileptic Drug Treatment in Newly Diagnosed Epilepsy Patients

    May 1, 2007, 00:00

  • PPN12 PETS, PEOPLE AND DEMAND FOR ETODOLAC IN THE UNITED STATES OF AMERICA

    May 1, 2007, 00:00

  • PUK1 A RETROSPECTIVE COMPARATIVE ANALYSIS OF TREATMENT OUTCOMES OF ALPHA-BLOCKERS IN THE MANAGEMENT OF BENIGN PROSTATIC HYPERPLASIA WITHIN A MANAGED CARE POPULATION

    May 1, 2007, 00:00

  • PMC35 THE ISSUES THAT ARISE DURING THE TRANSLATION OF IVRS (INTERACTIVE VOICE RESPONSE SYSTEM) EPRO SCRIPTS

    May 1, 2007, 00:00

  • PHP24 COMPARING MEDICATION ADHERENCE AND WASTAGE AMONG THREE DIFFERENT RETAIL PROGRAMS

    May 1, 2007, 00:00

  • PMH31 DRUG COST DEVELOPMENT OF CITALOPRAM AND FLUOXETINE FOLLOWING THE INTRODUCTION OF GENERIC SUBSTITUTION IN FINLAND

    May 1, 2007, 00:00

  • PST1 EPIDEMIOLOGY AND ECONOMIC BURDEN OF STROKE-RELATED RISK FACTORS-A SYSTEMATIC LITERATURE REVIEW

    May 1, 2007, 00:00

  • PHP29 REGULATION OF DRUG EXPENDITURES IN EUROPEAN COUNTRIES

    May 1, 2007, 00:00

  • PND26 MEASUREMENT OF QUALITY OF LIFE IN RESTLESS LEGS SYNDROME

    May 1, 2007, 00:00

  • CASE 1 REVIEWING THE REIMBURSEMENT STATUS OF PHARMACEUTICALS—EXPERIENCES FROM SWEDEN

    May 1, 2007, 00:00

  • PAA9 A 4-YEAR ASSESSMENT OF SEVERE AND NON-SEVERE ASTHMA IN A REAL-WORLD SETTING

    May 1, 2007, 00:00

  • PHP25 TRENDS IN OUT OF POCKET COST BURDEN FOR PATIENTS WITH CHRONIC CONDITIONS

    May 1, 2007, 00:00

  • PRS12 PROPENSITY OF PRESCRIBING FLUTICASONE/SALMETEROL COMBINATION IN A HIGH RISK MEDICAID POPULATION

    May 1, 2007, 00:00

  • PHP18 BENEFICIARY OUT-OF-POCKET-A CROSS-SECTIONAL PILOT STUDY IN THE SAUDI MINISTRY OF HEALTH HOSPITAL OUTPATIENT CLINICS

    May 1, 2007, 00:00

  • PPN17 QUANTIFYING HEALTH RELATED QUALITY OF LIFE IN A CHRONIC PAIN POPULATION- PRELIMINARY RESULTS

    May 1, 2007, 00:00

  • PCV57 HOW INFLUENTIAL ARE CLINICAL GUIDELINES FOR THE EVALUATION OF ACUTE CARDIAC SYMPTOMS? METHODOLOGY FOR THE INVESTIGATION OF NATIONAL CORONARY DISEASE IDENTIFICATION (INCIDENT)

    May 1, 2007, 00:00

  • PCN13 COST-EFFECTIVENESS ANALYSIS OF DOCETAXEL VERSUS OTHER REGIMENS IN THE ADJUVANT THERAPY OF EARLY AND LOCALLY ADVANCED BREAST CANCER IN POLAND

    May 1, 2007, 00:00

  • PCV29 PHARMACOECONOMIC ANALYSIS OF EXTENDED PROPHYLAXIS BY ENOXAPARIN AFTER HIP JOINT REPLACEMENT

    May 1, 2007, 00:00

  • PDB15 TREATMENT COSTS ATTRIBUTABLE TO OVERWEIGHT/OBESE IN PATIENTS WITH DIABETES MELLITUS IN THE U.S.ADULT POPULATION

    May 1, 2007, 00:00

  • PSM3 ESTIMATING THE INCIDENCE AND PREVALENCE OF SMOKING RELATED MORBIDITIES USING PROXY VALUES

    May 1, 2007, 00:00

  • PCASE13 OTC PROGRAM FOR COMMON, ROUTINE AILMENTS DESIGNED TO LOWER THE BURDEN ON PROVIDERS AND TO SUBSTITUTE LESS EXPENSIVE OTC MEDICATIONS FOR MORE COSTLY PRESCRIPTION MEDICATIONS-A CASE STUDY OF THE UNITED STATES NAVAL HOSPITAL IN KEFLAVI ...

    May 1, 2007, 00:00

  • PAA24 ASTHMA CONTROL AND HEALTH-RELATED QUALITY OF LIFE IN CHILDREN

    May 1, 2007, 00:00

  • PUK4 HAEMOGLOBIN FLUCTUATIONS IN HAEMODIALYSIS PATIENTS RECEIVING INTRAVENOUS EPOETIN ALFA OR INTRAVENOUS DARBEPOETIN ALFA

    May 1, 2007, 00:00

  • PHM7 COMPARISON OF EPOETIN ALFA AND DARBEPOETIN ALFA DOSES ROUTINELY USED IN CLINICAL PRACTICE IN DEPARTMENT OF DEFENSE BENEFICIARIES

    May 1, 2007, 00:00

  • CS4 A METHODOLOGY FOR PROJECTING DISEASE PREVALENCE, TREATMENT, AND EXPENDITURES FOR THE US EMPLOYERINSURED POPULATION

    May 1, 2007, 00:00

  • PDB12 RESOURCE UTILIZATION AND ECONOMIC COST OF CARE BASED ON A RANDOMIZED TRIAL OF V.A.C.® THERAPY IN THE TREATMENT OF DIABETIC FOOT ULCER WOUNDS

    May 1, 2007, 00:00

  • PMC23 CONSISTENCY OF MINIMAL IMPORTANT DIFFERENCES FOR MAPPED UTILITY INSTRUMENTS IN FOUR MAJOR PATIENT GROUPS

    May 1, 2007, 00:00

  • PCV54 PROJECTED COST SAVINGS COMPARISON TO MANAGED CARE ORGANIZATIONS FOR THE YEAR FOLLOWING GENERIC SIMVASTATIN AND PRAVASTATIN AVAILABILITY IN THE US

    May 1, 2007, 00:00

  • PDB6 RACIAL DIFFERENCES IN HOSPITALIZATIONS ASSOCIATED WITH MEDICATION USE IN MEDICAID ENROLLEES WITH TYPE 2 DIABETES

    May 1, 2007, 00:00

  • PHP33 PRELIMINARY EFFECTS OF A NEW NURSE-PHARMACIST CLINICAL PREVENTION PROGRAM ON MEDICATION USE

    May 1, 2007, 00:00

  • PAR11 ECONOMIC EVALUATION OF BIOLOGIC RESPONSE MODIFIER SPECIALTY PHARMACY PRIOR AUTHORIZATION PROGRAM

    May 1, 2007, 00:00

  • PGI16 VALIDATION OF GASTROINTESTINAL QUALITY OF LIFE INDEX FOR ASSESSMENT OF GALLSTONE-RELATED SYMPTOMS

    May 1, 2007, 00:00

  • PCN33 ANALYSIS OF DRUG REQUIREMENT FOR TREATMENT ADVANCED HODGKIN'S DISEASE

    May 1, 2007, 00:00

  • PCV25 THE ECONOMIC AND HEALTH CONSEQUENCES IN MEXICO OF MANAGING HYPERTENSION AND HYPERCHOLESTEROLEMIA WITH A SINGLE PILL THERAPY

    May 1, 2007, 00:00

  • PCASE3 USING OUTCOMES RESEARCH TO SUPPORT ANITBIOTIC SELECTION

    May 1, 2007, 00:00

  • MD4 MEDICAID PREFERRED DRUG LISTS' COSTS TO PHYSICIANS

    May 1, 2007, 00:00

  • PMH3 ANTIDEPRESSANT PROPHYLAXIS FOR POST-STROKE DEPRESSION-A META-ANALYSIS

    May 1, 2007, 00:00

  • PDB3 A RETROSPECTIVE EVALUATION OF HBA1C GOAL ATTAINMENT AMONG VARIOUS DIABETES TREATMENT REGIMENS IN A MANAGED CARE POPULATION

    May 1, 2007, 00:00

  • PUK7 GENERIC SUBSTITUTION OF TACROLIMUS AFTER RENAL TRANSPLANTATION-A DECISION-MAKING MODEL TO WEIGH RISKS AND BENEFITS

    May 1, 2007, 00:00

  • PIN19 COST-EFFECTIVENESS OF GARGLING FOR PREVENTION OF UPPER RESPIRATORY TRACT INFECTIONS

    May 1, 2007, 00:00

  • PHM2 STUDY OF ANEMIA IN LONG-TERM CARE (SALT)- RELATIONSHIP BETWEEN ANEMIA AND FALLS IN THE NURSING HOME SETTING

    May 1, 2007, 00:00

  • PHP47 DETERMINING ANTIBIOTIC USE IN INDIA

    May 1, 2007, 00:00

  • CASE 2 COST CONTROL FOR MENTAL HEALTH

    May 1, 2007, 00:00

  • PMH2 DIVALPROEX SODIUM VERSUS VALPROIC ACID- DRUG UTILIZATION PATTERNS, PERSISTENCE RATES, AND PREDICTORS OF HOSPITALIZATION AMONG VA PATIENTS DIAGNOSED WITH BIPOLAR DISORDER

    May 1, 2007, 00:00

  • PHM5 RESTROSPECTIVE STUDY OF OUTCOMES AND COSTS IN SICKLE CELL DISEASE (SCD) PATIENTS IN US

    May 1, 2007, 00:00

  • PIN29 DRUG PRICE, UTILIZATION AND SPENDING FOR ANTIRETROVIRAL MEDICATIONS IN U.S. MEDICAID PROGRAMS FROM 1991 TO 2005

    May 1, 2007, 00:00

  • PHP6 CHARACTERISTICS OF PATIENTS RECEIVING PHARMACEUTICAL SAMPLES AND ASSOCIATION BETWEEN SAMPLE USE AND OUT-OF-POCKET PRESCRIPTION COSTS

    May 1, 2007, 00:00

  • PUK8 COST EFFECTIVENESS OF ICODEXTRINE-BASED SOLUTIONS IN END STAGE RENAL DISEASE PATIENTS UNDERGOING PERITONEAL DIALYSIS THERAPY

    May 1, 2007, 00:00

  • PCN20 COST-OF-ILLNESS- ECONOMIC EVALUATION OF PALLIATIVE 153SM-LEXIDRONAM RADIONUCLIDE TREATMENT IN PATIENTS WITH BONE PAIN SECONDARY TO METASTATIC PROSTATE CANCER

    May 1, 2007, 00:00

  • PAA16 PREDICTORS OF THE PRESCRIBING OF ASTHMA PHARMACOTHERAPY IN THE AMBULATORY PATIENT POPULATION OF THE UNITED STATES

    May 1, 2007, 00:00

  • PCN30 A COST—UTILITY ANALYSIS MODEL FOR THE SECOND LINE TREATMENT OF METASTATIC RENAL CELL CARCINOMA IN MEXICO

    May 1, 2007, 00:00

  • PCASE7 INCLUDING A PHARMACOECONOMIC MODEL IN THE FORMULARY REVIEW PROCESS OF NEW

    May 1, 2007, 00:00

  • PAA2 EXACERBATION RATES FOR SINGLE VS. DUAL CONTROLLER THERAPY FOR MILD-PERSISTENT ASTHMA

    May 1, 2007, 00:00

  • PCN7 COST-EFFECTIVENESS ANALYSIS OF ADJUVANT THERAPY WITH TRASTUZUMAB FOR HER2-POSITIVE EARLY BREAST CANCER IN POLISH SETTING

    May 1, 2007, 00:00

  • PMH42 IMPACT OF ALTERNATIVE CENSORING SPECIFICATIONS ON TIME-TO-EVENT ANALYSES COMPARING ALTERNATIVE MEDICATIONS

    May 1, 2007, 00:00

  • PST7 DOES ADMINISTRATION MODE AFFECT ITEM HIERARCHY IN STROKE SPECIFIC QUALITY OF LIFE MEASURE, STROKE IMPACT SCALE?—TELEPHONE AND MAIL ADMINISTRATION METHODS

    May 1, 2007, 00:00

  • PCN17 MEDICAL COST CONSIDERATIONS OF FIXED DOSING REGIMENS OF ERYTHROPOIETIC AGENTS IN PATIENTS WITH CHEMOTHERAPY-INDUCED ANEMIA

    May 1, 2007, 00:00

  • PCN56 RELATIONSHIP BETWEEN FUNCTIONAL STATUS AND SELF RATED HEALTH IN PATIENTS WITH PROSTATE CANCER- DATA FROM CAPSURE

    May 1, 2007, 00:00

  • PMH26 ACCESS TO ILLICT DRUGS- POLICY IMPLICATIONS FROM THE 2003 NATIONAL SURVEY

    May 1, 2007, 00:00

  • CS2 OUTCOMES ASSOCIATED WITH THE USE OF THIAZOLIDINEDIONES AMONG MEDICARE BENEFICIARIES WITH TYPE II DIABETES—AN INSTRUMENTAL VARIABLE APPROACH

    May 1, 2007, 00:00

  • PCN15 COST-EFFECTIVENESS OF NEW TARGETED THERAPY SUNITINIB MALATE AS SECOND LINE TREATMENT IN METASTATIC RENAL CELL CARCINOMA IN ARGENTINA

    May 1, 2007, 00:00

  • PIN5 CLINICAL AND ECONOMIC OUTCOMES OF VANCOMYCIN FOR GRAM-POSITIVE INFECTIONS IN AN ERA OF INCREASING RESISTANCE-A SYSTEMATIC REVIEW

    May 1, 2007, 00:00

  • PAA7 PHARMACOECONOMIC OUTCOMES OF LEVALBUTEROL AND RACEMIC ALBUTEROL IN HOSPITALIZED PATIENTS REQUIRING NEBULIZATION THERAPY (POLARIS)

    May 1, 2007, 00:00

  • PCV2 CLINICAL EXPERIENCE IN DYSLIPIDEMIC PATIENTS TREATED EITHER WITH ROSUVASTATIN 10 MG/DAY OR EZETIMIBE/SIMVASTATIN 10/20 MG/DAY IN MEXICO CITY. A RETROSPECTIVE ANALYSIS

    May 1, 2007, 00:00

  • PCV32 IMPACT OF DEPRESSION ON HEALTH STATUS AND HEALTH CARE UTILIZATION IN PATIENTS WITH HYPERTENSION- RESULTS FROM THE MEDICAL EXPENDITURE PANEL SURVEY (MEPS 2002-2003)

    May 1, 2007, 00:00

  • PMH8 FORECASTING U.S. MEDICAID PROGRAM EXPENDITURE ON ANTIDEPRESSANT DRUGS

    May 1, 2007, 00:00

  • IN4 ECONOMIC EVALUATION OF INFLUENZA PANDEMIC MITIGATION STRATEGIES IN THE US USING A STOCHASTIC MICROSIMULATION INFLUENZA MODEL

    May 1, 2007, 00:00

  • PGI14 ONE WEEK VERSUS DAILY RECALL OF SYMPTOMS OF INFANT GERD- DOES IT MAKE A DIFFERENCE?

    May 1, 2007, 00:00

  • PCV47 BURDEN OF ILLNESS AMONG PATIENTS AT HIGH RISK FOR MAJOR CARDIOVASCULAR EVENTS

    May 1, 2007, 00:00

  • PMC19 HOW GOOD IS GOOD ENOUGH? INTERNAL VALIDITY OF STATED PREFERENCES FOR DRUG THERAPIES

    May 1, 2007, 00:00

  • PDB22 INFLUENCE OF HEMOGLOBIN A1C TEST RESULT ON DECISION TO INITIATE INSULIN SUPPLEMENTATION IN TYPE 2 DIABETES

    May 1, 2007, 00:00

  • WH3 REDUCED WORK LIMITATION WITH IMPROVEMENT IN MOOD, SLEEP AND VASOMOTOR SYMPTOMS IN POSTMENOPAUSAL WOMEN

    May 1, 2007, 00:00

  • Estimating the Rate of Accumulating Drug Resistance Mutations in the HIV Genome

    May 1, 2007, 00:00

  • PMC14 PREDICTORS OF SELF-RATED HEALTH STATUS AMONG GENERAL POPULATION IN THE UNITED STATES USING THE MEDICAL EXPENDITURE PANEL SURVEY (MEPS)

    May 1, 2007, 00:00

  • PPN4 ECONOMICS OF MORPHINE EQUIVALENT DAILY DOSES (MEDD)

    May 1, 2007, 00:00

  • AR3 CAUSES AND EFFECTS OF SCENARIO REJECTION- STATED PREFERENCES FOR RHEUMATOID ARTHRITIS TREATMENTS

    May 1, 2007, 00:00

  • RS2 INCREMENTAL COSTS ASSOCIATED WITH ANTIBIOTICS PRESCRIBED FOR COMMUNITY ACQUIRED PNEUMONIA

    May 1, 2007, 00:00

  • PHP32 THE STATE OF HEALTH STATUS MEASUREMENT IN LATIN AMERICA

    May 1, 2007, 00:00

  • PUK2 OUTCOMES AND COSTS ASSOCIATED WITH IMMUNOSUPPRESSION COMPLIANCE

    May 1, 2007, 00:00

  • PEN1 ESTIMATING THE QALY BENEFITS OF TREATMENT FOR GROWTH HORMONE DEFICIENCY (GHD) IN ADULT PATIENTS-A PRECURSOR TO COST-EFFECTIVENESS ANALYSIS

    May 1, 2007, 00:00

  • PSU3 SAVINGS OF THE USE OF RHBMP-2 IN OPEN TIBIA FRACTURES FOR EUROPEAN HEALTH CARE SYSTEMS FROM A PAYER AND SOCIETAL PERSPECTIVE

    May 1, 2007, 00:00

  • PHP20 IMPACT OF POLYPHARMACY MEDICATION THERAPY MANAGEMENT PROGRAM (MTMP) ON DRUG EXPENDITURES IN MEDICARE PART D POPULATION

    May 1, 2007, 00:00

  • PMC1 FORECASTING WITH TIME SERIES MODELS TO EXAMINE THE AVAILABILITY OF INPATIENT BEDS

    May 1, 2007, 00:00

  • PCASE6 CLINICAL OUTCOMES ASSESSMENT IN BEHAVIORAL HEALTH CARE- SEARCHING FOR PRACTICAL SOLUTIONS

    May 1, 2007, 00:00

  • PIN11 COST-EFFECTIVENESS OF SUBSTITUTING LAMIVUDINE (LVD) WITH ENTECAVIR (ETV) IN CHRONIC HEPATITIS B (CHB) PATIENTS IN THE PUBLIC SECTOR OF HONG KONG

    May 1, 2007, 00:00

  • PMH33 PROFILING UTILIZATION PATTERNS OF ANTIPSYCHOTICS AMONG PATIENTS WITH BIPOLAR DISORDER-A CLAIMS DATA ANALYSIS

    May 1, 2007, 00:00

  • PCV20 A COST-EFFECTIVENESS STUDY COMPARING IVABRADINE WITH STANDARD CARE IN STABLE ANGINA PECTORIS IN THE NETHERLANDS

    May 1, 2007, 00:00

  • PCN18 BURDEN OF ILLNESS ANALYSIS OF MALIGNANT METASTATIC MELANOMA IN THE UNITED STATES

    May 1, 2007, 00:00

  • PPN16 PRESCRIBING OF FENTANYL PATCHES TO NON-OPIOID TOLERANT PATIENTS IN THE MILITARY HEALTH SYSTEM (MHS)

    May 1, 2007, 00:00

  • PDB17 DETERMINATION OF HEALTH CARE COSTS INCURRED BY SWEDISH PATIENTS WITH TYPE 2 DIABETES

    May 1, 2007, 00:00

  • PAR16 A COMPARISON OF SWITCHING PATTERNS AMONG ANTITUMOR NECROSIS FACTORS (ANTI-TNFS) IN THE TREATMENT OF RHEUMATOID ARTHRITIS

    May 1, 2007, 00:00

  • PCASE1 APPLICATION OF PHARMACOECONOMICS TO DOD'S ANTILIPIDEMIC-1 UNIFORM FORMULARY DECISION

    May 1, 2007, 00:00

  • PCV31 COST-EFFECTIVENESS OF ACHIEVING ADDITIONAL LIPID TARGETS WHEN SUBSTITUTING FENOFIBRATE 145 MG FOR STANDARD FENOFIBRATE THERAPY

    May 1, 2007, 00:00

  • PMH23 ECONOMIC EVALUATION OF LONG ACTING TREATMENTS FOR ATTENTION-DEFICIT/HYPERACTIVITY DISORDER IN THE MILITARY HEALTH SYSTEM

    May 1, 2007, 00:00

  • PDB25 HEALTH STATUS AND QUALITY OF LIFE IN TYPE 2 DIABETES MELLITUS- RELATIONSHIPS IN A CROSS-SECTIONAL STUDY

    May 1, 2007, 00:00

  • PIH10 BURDEN OF PREMENSTRUAL DYSPHORIC DISORDER ON HEALTH-RELATED QUALITY OF LIFE

    May 1, 2007, 00:00

  • PCN2 ASSESSING THE NET HEALTH OUTCOMES OF A 4D ELECTROMAGNETIC TUMOR TRACKING SYSTEM DURING RADIOTHERAPY FOR CLINICALLY LOCALIZED PROSTATE CANCER-A HEALTH TECHNOLOGY ASSESSMENT OF THE CALYPSO® 4D LOCALIZATION SYSTEM WITH BEACON® TRANSPONDER ...

    May 1, 2007, 00:00

  • PCV44 EFFECTS OF MEDICAID ACCESS RESTRICTIONS ON STATIN UTILISATION FOR PATIENTS TREATED BY PHYSICIANS PRACTISING IN POOR AND MINORITY NEIGHBORHOODS

    May 1, 2007, 00:00

  • PCN40 PATTERNS OF TREATMENT OF NON SMALL CELL LUNG CANCER (NSCLC) IN COMMUNITY PRACTICE

    May 1, 2007, 00:00

  • PCN1 COLONIC STENTING VERSUS SURGERY FOR MALIGNANT LARGE BOWEL OBSTRUCTION- COMPARATIVE ASSESSMENT OF OUTCOMES AND COST

    May 1, 2007, 00:00

  • PCV13 METABOLIC SYNDROME PREVALENCE IN A HYPERTENSIVE POPULATION

    May 1, 2007, 00:00

  • PMH7 SUICIDALITY AND ANTIDEPRESSANTS USE IN CHILDREN AND ADOLESCENTS

    May 1, 2007, 00:00

  • PCN3 CORRELATION BETWEEN TIME TO PROGRESSION AND OVERALL SURVIVAL IN PATIENTS WITH METASTATIC BREAST CANCER

    May 1, 2007, 00:00

  • PCN38 WITHIN COUNTRY DIFFERENCES IN MAMMOGRAPHY COVERAGE OF THE HUNGARIAN NATIONWIDE ORGANIZED BREAST CANCER SCREENING PROGRAMME

    May 1, 2007, 00:00

  • MC4 TIME HORIZON BIAS IN ECONOMIC EVALUATIONS

    May 1, 2007, 00:00

  • PDB11 THE COST-EFFECTIVENESS OF VACUUM ASSISTED CLOSURE® (V.A.C.) THERAPY FOR THE TREATMENT OF DIABETIC FOOT WOUNDS

    May 1, 2007, 00:00

  • PEY13 ADJUNCTIVE THERAPY USE BY GLAUCOMA PATIENTS ON ORAL ANTIHYPERTENSIVES

    May 1, 2007, 00:00

  • PIN3 TREATMENT FAILURE, COMPLICATIONS AND COSTS OF LEVOFLOXACIN VS.AMOXICILLIN/CLAVULANATE ANTIBIOTIC THERAPY IN OUTPATIENT COMMUNITY ACQUIRED PNEUMONIA (CAP)

    May 1, 2007, 00:00

  • PCV53 PROFILES OF INITIAL DRUG THERAPIES AMONG NEWLY DIAGNOSED HYPERTENSIVE PATIENTS WITH NO COMPELLING INDICATIONS

    May 1, 2007, 00:00

  • PMC24 PSYCHOMETRIC EVALUATION OF INSTRUMENTS USED TO MEASURE PATIENT SATISFACTION WITH PHARMACIST SERVICES

    May 1, 2007, 00:00

  • Substantial Treatment Overuse in the United States?—Response to Grandjour

    May 1, 2007, 00:00

  • CN4 PSYCHOMETRIC VALIDATION OF A PATIENT SYMPTOM ASSESSMENT-LUNG CANCER (PSALC) INSTRUMENT FOR SMALL CELL LUNG CANCER (SCLC)

    May 1, 2007, 00:00

  • PGI18 GASTROESOPHAGEAL REFLUX DISEASE AND HEALTHRELATED QUALITY OF LIFE IN THE GENERAL POPULATION OF SHANGHAI, CHINA

    May 1, 2007, 00:00

  • PST6 GENERIC AND DISEASE-SPECIFIC HEALTH RELATED QUALITY OF LIFE (HRQOL) IN STROKE SURVIVORS

    May 1, 2007, 00:00

  • The Relationship between Influenza Vaccination and Outpatient Visits for Upper Respiratory Infection by the Elderly in Taiwan

    Mar 1, 2007, 00:00

  • The Cost-Effectiveness of Expanding Newborn Screening for up to 21 Inherited Metabolic Disorders Using Tandem Mass Spectrometry- Results from a Decision-Analytic Model

    Mar 1, 2007, 00:00

  • Economic Burden of Osteoporosis-Related Fractures in Medicaid

    Mar 1, 2007, 00:00

  • Reduced Mortality Rates after Intensive Statin Therapy in Managed-Care Patients

    Mar 1, 2007, 00:00

  • Comment on “Where's the Value in Health Care?”

    Mar 1, 2007, 00:00

  • The Cost-Effectiveness of Influenza Vaccination for People Aged 50 to 64 Years- An International Model

    Mar 1, 2007, 00:00

  • Effect of Second-Generation Antidepressants on Mania- and Depression-Related Visits in Adults with Bipolar Disorder- A Retrospective Study

    Mar 1, 2007, 00:00

  • The Author's Reply to Comment on “Where's the Value in Health Care?”

    Mar 1, 2007, 00:00

  • The Impact of Atrial Fibrillation on the Cost of Stroke- The Berlin Acute Stroke Study

    Mar 1, 2007, 00:00

  • Health-Related Quality of Life Measured with EQ-5D in Patients Treated for Depression in Primary Care

    Mar 1, 2007, 00:00

  • Cost-Effectiveness Analysis of a Quality-Controlled Mammography Screening Program from the Swiss Statutory Health-Care Perspective- Quantitative Assessment of the Most Influential Factors

    Jan 1, 2007, 00:00

  • Economic Evaluation of Palliative Management versus Peritoneal Dialysis and Hemodialysis for End-Stage Renal Disease- Evidence for Coverage Decisions in Thailand

    Jan 1, 2007, 00:00

  • Cardioverter Defibrillators in Primary Prevention of Sudden Cardiac Death- A Cost or an Investment?

    Jan 1, 2007, 00:00

  • A Checklist for Medication Compliance and Persistence Studies Using Retrospective Databases

    Jan 1, 2007, 00:00

  • Is It Time for Managed Care Organizations to Cover Weight Reduction?

    Jan 1, 2007, 00:00

  • The Effect of Disease, Functional Status, and Relapses on the Utility of People with Multiple Sclerosis in the UK

    Jan 1, 2007, 00:00

  • Using EQ-5D to Derive General Population-based Utilities for the Quality of Life Assessment of Growth Hormone Deficiency in Adults (QoL-AGHDA)

    Jan 1, 2007, 00:00

  • Assessment of Cardiometabolic Risk Factors in a National Primary Care Electronic Health Record Database

    Jan 1, 2007, 00:00

  • Economic Burden and Risk of Cardiovascular Disease and Diabetes in Patients with Different Cardiometabolic Risk Profiles

    Jan 1, 2007, 00:00

  • Metabolic Syndrome and Employer Sponsored Medical Benefits- An Actuarial Analysis

    Jan 1, 2007, 00:00

  • Cost-Effectiveness of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting Associated with Highly Emetogenic Chemotherapy

    Jan 1, 2007, 00:00

  • Predicting the Prevalence of Cardiometabolic Risk Factors When Clinical Data Are Limited

    Jan 1, 2007, 00:00

  • The Cost-Effectiveness of Lanthanum Carbonate in the Treatment of Hyperphosphatemia in Patients with End-Stage Renal Disease

    Jan 1, 2007, 00:00

  • Special Issue- Exploring Cardiometabolic Complications of Obesity and Related Risk Factors- Prevalence and Economic Consequences

    Jan 1, 2007, 00:00

  • Foreword- Exploring Cardiometabolic Complications of Obesity and Related Risk Factors- Prevalence and Economic Consequences

    Jan 1, 2007, 00:00

  • Age-Specific Impact of Obesity on Prevalence and Costs of Diabetes and Dyslipidemia

    Jan 1, 2007, 00:00

  • Cost-Benefit Analysis of Preventing Sudden Cardiac Deaths with an Implantable Cardioverter Defibrillator versus Amiodarone

    Jan 1, 2007, 00:00

  • Simple Demographic Model to Predict Multiple Cardiometabolic Risk Factors in Two Well-Known Observational Cohorts

    Jan 1, 2007, 00:00

  • Cardiovascular Risk Factor Clusters and Employment in the United States

    Jan 1, 2007, 00:00

  • PDB29 COMPARING THE DEVELOPMENT OF A GERMAN DIABETES POPULATION WITH RESPECT TO LONGTERM OUTCOMES USING DATA FROM THE DETECT STUDY AND THE EAGLE DIABETES SIMULATION MODEL

    Nov 1, 2006, 00:00

  • PCV3 DO WE FOLLOW THE GUIDELINES ON PREVENTION OF CARDIOVASCULAR DISEASE IN OUT-PATIENT CARE?

    Nov 1, 2006, 00:00

  • PMH19 IMPACT OF REMISSION IN MAJOR DEPRESSIVE DISORDER ON ECONOMIC BURDEN OF ILLNESS IN SWEDEN

    Nov 1, 2006, 00:00

  • PUK20 PATIENTS UNDER 65 YEARS OF AGE ON RENAL TRANSPLANT WAITING LISTS SHOW A WORSE PERCEIVED STATE OF HEALTH THAN OLDER ONES

    Nov 1, 2006, 00:00

  • PDB22 EVALUATING THE LONG-TERM HEALTH OUTCOMES AND ECONOMICS OF INITIATING BIPHASIC ANALOG INSULIN COMPARED TO OPTIMIZED ORAL THERAPY ALONE

    Nov 1, 2006, 00:00

  • PCV9 NON-PERSISTENT USE OF ANTIHYPERTENSIVE DRUGS LEADS TO INCREASED RISK OF HOSPITALIZATIONS FOR ACUTE MYOCARDIAL INFARCTION OR STROKE

    Nov 1, 2006, 00:00

  • OA2 SCREENING FOR PATIENTS AT RISK FOR OSTEOPOROSIS BASED ON A RISK-QUESTIONNAIRE IN A GERMAN SETTING OF COMMUNITY PHARMACIES

    Nov 1, 2006, 00:00

  • PHP2 RACIAL/ETHNIC DISPARITIES IN PRESCRIPTION DRUG UTILIZATION AND OUT-OF-POCKET COSTS

    Nov 1, 2006, 00:00

  • PCN67 PREVENTION OF CHEMOTHERAPY INDUCED NAUSEA AND VOMITING WITH 5HT3 RECEPTOR ANTAGONISTS AND HEALTH RELATED QOL

    Nov 1, 2006, 00:00

  • PMC13 EMPIRICAL RESEARCH FOR WILLINGNESSTO PAYFOR ONE QALY GAIN

    Nov 1, 2006, 00:00

  • PCV14 ASCOT-LIKE PATIENT PREVALENCE AMONG THE HYPERTENSIVES IN SPAIN

    Nov 1, 2006, 00:00

  • MC2 15DS-A NEW DYNAMIC QUALITY OF LIFE TOOL WITH INCREASED SENSITIVITY AND IMPROVED COMPOSITE STRUCTURE FOR RECALL BIAS AND RESPONSE SIFT ADJUSTMENTS

    Nov 1, 2006, 00:00

  • PCV15 ANALYSIS OF PRESCRIBING PATTERNS OF ANTIHYPERTENSIVE AGENTS (AA) BEFORE AND AFTER PUBLICATION OF THE ANTIHYPERTENSIVE AND LIPIDLOWERING TREATMENT TO PREVENT HEART ATTACK TRIAL (ALLHAT)

    Nov 1, 2006, 00:00

  • PEY16 COST-UTILITY ANALYSIS FOR PEGAPTANIB IN AGE-RELATED MACULAR DEGENERATION IN THE UK- THE IMPACT OF DEMOGRAPHIC AND DISEASE CHARACTERISTICS

    Nov 1, 2006, 00:00

  • PEY23 VISION WITH RESTOR® VERSUS MONOFOCAL INTRAOCULAR LENSES (IOL) AFTER CATARACT SURGERY- RESULTS OF A POOLED ANALYSIS

    Nov 1, 2006, 00:00

  • PDB41 EFFECT OF COMPLICATIONS ON HEALTH RELATED QUALITY OF LIFE IN HUNGARIAN INSULIN TREATED DIABETIC PATINETS

    Nov 1, 2006, 00:00

  • PIN32 VALIDATION OF THE PATIENTS' ATTITUDES AND PERCEPTIONS TOWARDS HAART QUESTIONNAIRE

    Nov 1, 2006, 00:00

  • PSU3 DEMOGRAPHIC PREDICTORS OF RESOURCE UTILIZATION AND COSTS OF SOLID ORGAN TRANSPLANTATION IN BRITISH COLUMBIA, CANADA

    Nov 1, 2006, 00:00

  • PIN23 INDICATOR OF ANTIBIOTIC USE IN PUBLIC PHARMACY CHAIN BELGRADE

    Nov 1, 2006, 00:00

  • POS9 COMPARISON OF THE BURDEN OF ILLNESS OF DISPLACED AND UNDISPLACED FEMORAL NECK FRACTURE AFTER REDUCTION INTERNAL FIXATION

    Nov 1, 2006, 00:00

  • PCV17 PROJECTED IMPACT ON CORONARY HEART DISEASE OF ADDING PROLONGED-RELEASE NICOTINIC ACID (NIASPAN®) TO STATIN TREATMENT IN EUROPEAN PATIENTS WITH TYPE 2 DIABETES

    Nov 1, 2006, 00:00

  • PMC9 A REVIEW OF FACTORS AFFECTING THERAPEUTIC COMPLIANCE

    Nov 1, 2006, 00:00

  • PCV73 ANALYSIS OF COST AND EFFECTIVENESS DATA USING RANDOM PERMUTATION METHODS

    Nov 1, 2006, 00:00

  • PUK22 COMPARISON OF THE PRO ENDPOINTS FOUND IN LABELING CLAIMES OF URINARY INCONTINENCE DRUGS WITH THOSE RECOMMENDED BY THE CORRESPONDING EMEA NOTE FOR GUIDANCE

    Nov 1, 2006, 00:00

  • PDB42 PATIENT AND PHYSICIAN DRIVERS OF HEALTH-RELATED QUALITY LIFE OF PATIENTS WITH TYPE 2 DIABETES IN PRIMARY CARE IN SPAIN

    Nov 1, 2006, 00:00

  • IH3 FEASIBILITY AND PRIMARY VALIDITY OF A GERMAN EQ-5D CHILDREN'S VERSION

    Nov 1, 2006, 00:00

  • POS16 LONG TERM QUALITY OF LIFE RELATED TO OSTEOPOROTIC FRACTURES; 13–18 MONTHS AFTER FRACTURE

    Nov 1, 2006, 00:00

  • PMH35 REDUCTION IN SUICIDAL IDEATION AND VIOLENT BEHAVIOUR AFTER SIX MONTHS OF TREATMENT WITH LONG ACTING RISPERIDONE IN PATIENTS ENROLLED IN THE ELECTRONIC SCHIZOPHRENIA ADHERENCE TREATMENT REGISTRY (E-STAR)

    Nov 1, 2006, 00:00

  • CN4 COST-EFFECTIVENESS OF ERLOTINIB COMPARED WITH DOCETAXEL FOR THE TREATMENT OF RELAPSED NONSMALL CELL LUNG CANCER (NSCLC) IN THE UK

    Nov 1, 2006, 00:00

  • PEY24 METRIC PROPERTIES OF THE MACDQOL IN FRENCH, GERMAN, ITALIAN, AND AMERICAN POPULATIONS- AN INDIVIDUALISED QOL INSTRUMENT SPECIFIC TO MACULAR DISEASE (MD)

    Nov 1, 2006, 00:00

  • PCN35 BURDEN OF ILLNESS OF RENAL CELL CARCINOMA IN SPAIN

    Nov 1, 2006, 00:00

  • PHM3 HEPARIN-RELATED THROMBOCYTOPENIA ASSOCIATED WITH MAJOR INCREASE IN HOSPITAL COSTS

    Nov 1, 2006, 00:00

  • PRS7 ESTIMATION OF MORBIDITY, RESOURCE UTILIZATION AND COST IN SUBJECTS TREATED WITH TIOTROPIUM BROMIDE FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) IN A SPANISH POPULATION SETTING

    Nov 1, 2006, 00:00

  • PSU2 ECONOMIC EVALUATION COMPARING FROM HOME TO OPERATION AND CONVENTIONAL PROCESS OF LAPAROSCOPIC CHOLECYSTECTOMY- PROSPECTIVE RANDOMIZED CONTROLLED TRIAL

    Nov 1, 2006, 00:00

  • PUK6 COST-EFFECTIVENESS OF TREATMENT WITH EPOIETIN ALPHA FOR PATIENTS WITH ANAEMIA DUE TO RENAL FAILURE—THE CASE OF SWEDEN

    Nov 1, 2006, 00:00

  • PIN24 THE USE OF ANTIBIOTICS IN CHILDREN POPULATION IN BELGRADE REGION

    Nov 1, 2006, 00:00

  • PAA9 THE EFFECTS OF GENERIC-ONLY DRUG COVERAGE ON INHALED CORTICOSTEROID EXPENDITURES AND USE

    Nov 1, 2006, 00:00

  • PAA2 EFFECT OF SUBLINGUAL IMMUNOTHERAPY (SLIT) ON DIRECT MEDICAL COSTS FOR PATIENTS WITH ALLERGIC RHINITIS AND ASTHMA- RESULTS FROM THE SIMAP DATABASE STUDY

    Nov 1, 2006, 00:00

  • PND4 PREGABALIN VS GABAPENTIN IN THE TREATMENT OF NEUROPATHIC PAIN IN ITALY- A COST-EFFECTIVENESS ANALYSIS

    Nov 1, 2006, 00:00

  • PEY27 DEVELOPMENT OF A QUESTIONNAIRE ASSESSING PATIENT SATISFACTION WITH EYE DROPS IN OCULAR HYPERTENSION AND GLAUCOMA

    Nov 1, 2006, 00:00

  • PCN68 QUALITY OF LIFE OF PATIENTS RECEIVING ADJUVANT CHEMOTHERAPIES FOR BREAST CANCER IN JAPAN

    Nov 1, 2006, 00:00

  • RS3 THE COST-EFFECTIVENESS OF TIOTROPIUM VERSUS IPRATROPIUM IN A US VETERANS POPULATION DIAGNOSED WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE

    Nov 1, 2006, 00:00

  • PMC14 MEASURING PATIENT-REPORTED SIDE EFFECTS OF DRUGS- ITS IMPORTANCE AND METHODOLOGICAL CHALLENGES

    Nov 1, 2006, 00:00

  • CV5 PHARMACOECONOMIC EVALUATION OF SIMVASTATIN VERSUS “NO TREATMENT” IN PRIMARY AND SECONDARY PREVENTION OF CORONARY HEART DISEASE (CHD) IN POLAND

    Nov 1, 2006, 00:00

  • HP1 CRITICAL APPRAISAL OF ECONOMIC EVALUATIONS OF CHOLESTEROL LOWERING DRUGS-A SYSTEMATIC REVIEW

    Nov 1, 2006, 00:00

  • PMH16 COST EFFECTIVENESS MODEL COMPARING FAST DISSOLVING OLANZAPINE AND CONVENTIONAL OLANZAPINE TABLETS IN THE TREATMENT OF SCHIZOPHRENIA

    Nov 1, 2006, 00:00

  • PSK2 MEDICATION ADHERENCE AND HEALTH CARE COSTS ASSOCIATED WITH BIOLOGICS IN MEDICAID-ENROLLED PATIENTS WITH PSORIASIS

    Nov 1, 2006, 00:00

  • CN1 TREATMENTS FOR METASTATIC MELANOMA- SYNTHESIS OF EVIDENCE FROM RANDOMIZED TRIALS

    Nov 1, 2006, 00:00

  • PIN30 PSYCHOMETRIC VALIDATION OF THE ACTIVITY IMPAIRMENT ASSESSMENT (AIA) QUESTIONNAIRE IN PATIENTS WITH ACUTE BACTERIAL SINUSITIS

    Nov 1, 2006, 00:00

  • PMH40 ASSESSING SELECTION BIAS ON TREATMENT EFFECTS IN OBSERVATIONAL STUDIES WITH REPEATED OUTCOME MEASURES- REGRESSION, PROPENSITY SCORING, FIXEDEFFECTS MODELS, AND BAYESIAN ESTIMATION METHODS

    Nov 1, 2006, 00:00

  • PMH45 CROSS-SECTIONAL EVALUATION OF HEALTH STATE UTILITY IN SWEDISH OUTPATIENTS SUFFERING FROM MAJOR DEPRESSIVE DISORDER

    Nov 1, 2006, 00:00

  • PIN1 CLINICAL AND ECONOMIC IMPACT OF INTRODUCING A QUADRIVALENT (6, 11, 16, 18) HUMAN PAPILLOMAVIRUS VACCINE IN SWITZERLAND

    Nov 1, 2006, 00:00

  • PND8 COST-EFFECTIVENESS OF TREATING RESTLESS LEGS PATIENTS WITH PRAMIPEXOLE COMPARED TO NO TREATMENT IN SWEDEN

    Nov 1, 2006, 00:00

  • PHM7 DIRECT COST OF BETA THALASSEMIA MAJOR- RESUTS FROM THE ITHACA STUDY

    Nov 1, 2006, 00:00

  • PAR10 THE COST-UTILITY OF ADALIMUMAB (HUMIRA®) IN PATIENTS WITH RHEUMATOID ARTHRITIS (RA) IN DENMARK

    Nov 1, 2006, 00:00

  • PCN50 BOWEL CANCER SCREENING. BALANCING COSTEFFECTIVENESS AND AFFORDABILITY

    Nov 1, 2006, 00:00

  • PST3 RESOURCE UTILIZATION AND COSTS OF STROKES IN A THIRD LEVEL HOSPITAL IN MÉXICO

    Nov 1, 2006, 00:00

  • PHP33 OCCUPATIONAL INJURIES- USE AND COST OF EMERGENCY DEPARTMENT FOR TREATMENT OF ACCIDENTAL HYPODERMIC NEEDLE PUNCTURES

    Nov 1, 2006, 00:00

  • PCV85 COMPLIANCE AND PERSISTENCE OF FIXED DOSE VERSUS FREE DOSE COMBINATION THERAPY WITH VALSARTAN AND HCTZ FOR PATIENTS WITH HYPERTENSION

    Nov 1, 2006, 00:00

  • PAR8 TRENDS IN PRESCRIPTION CLAIMS FOLLOWING THE WITHDRAWAL OF ROFECOXIB FROM THE CANADIAN MARKET

    Nov 1, 2006, 00:00

  • PAR6 COST-UTILITY ANALYSIS OF RITUXIMAB AS A NEW THERAPEUTIC OPTION FOR RHEUMATOID ARTHRITIS PATIENTS IN CANADA

    Nov 1, 2006, 00:00

  • POB3 BURDEN OF ILLNESS OF ABDOMINAL OBESITY- A RETROSPECTIVE CHART REVIEW

    Nov 1, 2006, 00:00

  • PGI12 GASTROINTESTINAL COMPLICATIONS INDUCED BY NONSTERIODAL ANTI-INFLAMMATORY DRUGS (NSAID)- EPIDEMIOLOGICAL EXTRAPOLATION FOR EUROPE AND ECONOMIC CONSIDERATIONS

    Nov 1, 2006, 00:00

  • PEY2 EFFECTIVENESS OF TRAVOPROST VERSUS DORZOLAMIDE + TIMOLOL FIXED COMBINATION IN FIRST LINE TREATMENT OF GLAUCOMA-ANALYZED FROM THE UK GENERAL PRACTITIONER RESEARCH DATABASE

    Nov 1, 2006, 00:00

  • PHP28 PILOT STUDY OF THE IMPACT OF NEW PRICING SCHEMA ON DRUG PRICES IN REPUBLIC SERBIA

    Nov 1, 2006, 00:00

  • PCN31 A COST MINIMISATION ANALYSIS OF NAVELBINE-CISPLATIN VERSUS GEMCITABINE-CISPLATIN IN ADVANCED NONSMALL CELL LUNG CANCER IN POLAND

    Nov 1, 2006, 00:00

  • SZ1 EFFECTIVENESS AND COSTS OF ATYPICAL VERSUS TYPICAL ANTIPSYCHOTIC TREATMENT FOR SCHIZOPHRENIA IN ROUTINE CARE

    Nov 1, 2006, 00:00

  • PDB12 CONTINUOUS SUBCUTANEOUS INSULIN INFUSION VERSUS MULTIPLE DAILY INJECTION OF INSULIN IN PATIENTS WITH TYPE 1 DIABETES-A LONG-TERM HEALTH ECONOMIC ANALYSIS IN THE NORWEGIAN AND SWEDISH SETTINGS

    Nov 1, 2006, 00:00

  • PCN39 COST-UTILITY ANALYSIS IN A FRENCH SETTING OF ADJUVANT THERAPY WITH HERCEPTIN IN PATIENTS WITH HER-2 POSITIVE BREAST CANCER

    Nov 1, 2006, 00:00

  • PND5 TREATMENT OF EARLY PARKINSONIAN PATIENTS WITH RASAGILINE OR ROPINIROLE. WHAT IS THE MOST COSTEFFECTIVE TREATMENT STRATEGY IN FINLAND?

    Nov 1, 2006, 00:00

  • PEY18 CHANGES IN MEDICAL AND SURGICAL TREATMENTS OF GLAUCOMA BETWEEN 1997 AND 2003 IN FRANCE

    Nov 1, 2006, 00:00

  • PAR2 ZOLEDRONIC ACID IN THE LONG-TERM MANAGEMENT OF PAGET'S DISEASE OF THE BONE IN GERMANY-A COSTSAVING APPROACH?

    Nov 1, 2006, 00:00

  • PSM2 COST-UTILITY ANALYSIS FOR SMOKING CESSATION THERAPY IN JAPAN

    Nov 1, 2006, 00:00

  • PGI6 THE USE OF BUDGET IMPACT MODELLING TO ASSESS THE ECONOMIC CONSEQUENCE OF CHANGING THE PRESCRIPTION PATTERN OF PROTON PUMP INHIBITORS (PPI) IN SWEDEN

    Nov 1, 2006, 00:00

  • PCV44 COMORBIDITIES, COSTS AND THERAPEUTIC GOALS ACHIEVED IN THE SECONDARY PREVENTION OF THE PRIMARY HEALTH CARE

    Nov 1, 2006, 00:00

  • PCN23 ADDING RITUXIMAB TO STANDARD CHEMOTHERAPY IS COST NEUTRAL AND CLINICALLY SUPERIOR IN ADVANCED STAGE NON-HODGKIN'S LYMPHOMA (NHL)

    Nov 1, 2006, 00:00

  • PCV78 TOWARDS A MODELLED ECONOMIC EVALUATION TO IDENTIFY THE OPTIMAL POPULATION FOR SCREENING OF CORONARY ARTERY DISEASE

    Nov 1, 2006, 00:00

  • PCN47 COUNTY LEVEL INEQUALITIES IN THE ATTENDANCE OF THE HUNGARIAN ORGANIZED NATIONWIDE CERVICAL CANCER SCREENING PROGRAMME

    Nov 1, 2006, 00:00

  • PCN22 COST-EFFECTIVENESS (CE) OF THE PREVENTION OF ORAL MUCOSITIS (OM) WITH KEPIVANCE® (PALIFERMIN) IN PATIENTS UNDERGOING MYELOABLATIVE THERAPY WITH AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) IN SPAIN

    Nov 1, 2006, 00:00

  • PRS19 EPIDEMIOLOGICAL STUDY TO INVESTIGATE PATIENTS' VIEWS ON CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)

    Nov 1, 2006, 00:00

  • PHM6 SOCIETAL COSTS OF ALLOGENEIC BLOOD TRANSFUSION IN THE NETHERLANDS

    Nov 1, 2006, 00:00

  • PMC11 EFFECTIVE USE OF ELECTRONIC DATA CAPTURE (EDC) TO IMPROVE THE QUALITY AND EFFICIENCY OF THE ANALYSIS OF PATIENT REPORTED OUTCOMES

    Nov 1, 2006, 00:00

  • POS11 EVOLUTION OF THE CONSUMPTION OF BISPHOSPHONATES AND RALOXIFENE FINANCED BY THE SPANISH NATIONAL HEALTH SYSTEM FOR OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN

    Nov 1, 2006, 00:00

  • DB1 RATES AND RISKS OF STARTING INSULIN IN DIABETES MELLITUS TYPE-2 PATIENTS

    Nov 1, 2006, 00:00

  • PHP19 DRUG PRICE INDICES 1980–2005 IN FINLAND

    Nov 1, 2006, 00:00

  • PAA3 COST OF MANAGING ASTHMA EXACERBATIONS WITH STABLE DOSING OF SALMETEROL/FLUTICASONE COMBINED PRODUCT (SFC) COMPARED WITH ADJUSTABLE MAINTENANCE DOSING (AMD) OF FORMOTEROL/BUDESONIDE COMBINED PRODUCT (FBC) IN POLAND

    Nov 1, 2006, 00:00

  • PDB38 ADHERENCE TO STATIN TREATMENT IN PEOPLE WITH TYPE 1 AND TYPE 2 DIABETES

    Nov 1, 2006, 00:00

  • PND11 MODELING LONG-TERM “REAL WORLD” OUTCOMES OF DISEASE-MODIFYING THERAPY IN RELAPSING-REMITTING ONSET MULTIPLE SCLEROSIS

    Nov 1, 2006, 00:00

  • PEY19 PROSTAGLANDIN AGONIST USE WITH AND WITHOUT ADJUNCTIVE THERAPY FOR THE TREATMENT OF GLAUCOMA- A CANADIAN POPULATION BASED ANALYSIS

    Nov 1, 2006, 00:00

  • PCV68 CLOPIDOGREL PATTERNS OF USE IN ACUTE CORONARY SYNDROME PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION IN 5 EUROPEAN COUNTRIES

    Nov 1, 2006, 00:00

  • PAA8 A COMPARISON OF CLAIMS RATIO BETWEEN PRIMARY AND SECONDARY DRUGS IN THE MANAGEMENT OF ASTHMA. A CANADIAN ANALYSIS

    Nov 1, 2006, 00:00

  • PCN64 DIFFERENTIAL ITEM FUNCTIONING USING RASCH ANALYSIS

    Nov 1, 2006, 00:00

  • PSK5 COST OF ATOPIC DERMATIS IN ADULTS- THE CODA STUDY

    Nov 1, 2006, 00:00

  • PDB35 COST-EFFECTIVENESS OF INHALED INSULIN IN PATIENTS WITH DIABETES UNCONTROLLED ON THEIR CURRENT THERAPY- THE UK BASE CASE SUBMITTED TO THE NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE (NICE)

    Nov 1, 2006, 00:00

  • PCN36 BURDEN OF CERVICAL CANCER IN POLAND

    Nov 1, 2006, 00:00

  • PSM1 THE HIGH COST OF CIGARETTE SMOKING IN GERMANY IN 2003

    Nov 1, 2006, 00:00

  • GI2 DICLOFENAC-ASSOCIATED ULCER RISK IS REDUCED BY PROTON PUMP INHIBITORS- NESTED CASE CONTROL STUDY

    Nov 1, 2006, 00:00

  • PEY22 MEDICATION ADHERENCE AND HEALTH CARE COSTS WITH INTRODUCTION OF LATANOPROST THERAPY FOR GLAUCOMA IN A MEDICARE MANAGED CARE POPULATION

    Nov 1, 2006, 00:00

  • PMH21 COST-UTILITY ANALYSIS OF ANTIDEPRESSANTS FOR SECOND-LINE TREATMENT OF MAJOR DEPRESSIVE DISORDER

    Nov 1, 2006, 00:00

  • PCV39 PHARMACOLOGICAL TREATMENT OF HYPERTENSION IN PATIENTS WITH TYPE II DIABETES A COST-MINIMIZATION ANALYSIS

    Nov 1, 2006, 00:00

  • PHP26 SUPPLY SIDE COST-CONTAINMENT IN GERMANY- WIN SOME, LOSE SOME

    Nov 1, 2006, 00:00

  • PHM14 PATIENT PREFERENCE AND WILLINGNESS-TO-PAY FOR ANTICOAGULANT TREATMENT OPTIONS IN PATIENTS RECEIVING ORAL ANTICOAGULANT TREATMENT (OAT)- A DISCRETE CHOICE EXERCISE

    Nov 1, 2006, 00:00

  • PCN62 UTILITY ELICITATION IN PATIENTS WITH FOLLICULAR LYMPHOMA

    Nov 1, 2006, 00:00

  • PDB23 THE COST-EFFECTIVENESS OF INHALED INSULIN IN SWEDEN

    Nov 1, 2006, 00:00

  • PAR11 ARE THEY MEASURABLE? A STUDY ON ELICITING INDIRECT AND INTANGIBLE COSTS OF KNEE OSTEOARTHRITIS USING HUMAN CAPITAL APPROACH AND WILLINGNESS-TO-PAY IN MULTIETHNIC ASIAN POPULATION IN SINGAPORE

    Nov 1, 2006, 00:00

  • PCV33 COST-EFFECTIVENESS MODEL TO EVALUATE MANAGED VENTRICULAR PACING (MVP) IMPLANTED IN A SPANISH AMBULATORY SURGERY PROGRAM

    Nov 1, 2006, 00:00

  • PUK11 COST UTILITY ANALYSIS OF ERYTHROPOIETIN THERAPY IN THE MINISTRY OF HEALTH DIALYSIS PROGRAMME

    Nov 1, 2006, 00:00

  • PHP12 WASTAGE OF MEDICINES IN PORTUGAL

    Nov 1, 2006, 00:00

  • POS8 THE SOCIETAL BURDEN OF OSTEOPOROSIS

    Nov 1, 2006, 00:00

  • PCN12 COST EFFECTIVENESS OF ERLOTINIB IN THE TREATMENT OF ADVANCED NON SMALL CELL LUNG CANCER (NSCLC) IN POLAND

    Nov 1, 2006, 00:00

  • PEY15 LATANOPROST VERSUS TIMOLOL MONOTHERAPY FOR THE TREATMENT OF GLAUCOMA-A COST-EFFECTIVNESS ANALYSIS IN SCANDINAVIA AND THE UK USING A DECISION-ANALYTIC HEALTH ECONOMIC MODEL

    Nov 1, 2006, 00:00

  • RS2 TREATMENT WITH INHALED CORTICOSTEROIDS IN ASTHMA TOO OFTEN DISCONTINUED

    Nov 1, 2006, 00:00

  • PCV41 A COST CONSEQUENCE ANALYSIS OF THE IMPACT OF JBS 2 ON PATIENTS ELIGIBLE FOR STATIN TREATMENT IN SCOTLAND

    Nov 1, 2006, 00:00

  • PRS18 MEASURING DISEASE-SPECIFIC UTILITIES FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE HEALTH- AND EXACERBATION PROFILES

    Nov 1, 2006, 00:00

  • PHP40 COST-EFFECTIVENESS STUDY OF ADJUSTED CLINICAL GROUPS TO ASSESS THE ABILITY OF SPANISH PRIMARY CARE TEAMS TO BRING ISSUES TO RESOLUTION

    Nov 1, 2006, 00:00

  • PSK9 QUALITY OF LIFE OF ADULT PATIENTS WITH ATOPIC DERMATITIS- THE CODA STUDY

    Nov 1, 2006, 00:00

  • PCV56 ESTIMATION OF THE PRESENCE OF CARDIOVASCULAR EVENTS AND DIRECT COSTS ASSOCIATED WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE IN AN AMBULATORY SETTING

    Nov 1, 2006, 00:00

  • POS4 COMPARING THE COST-EFFECTIVENESS OF RHBMP-2 IN THE TREATMENT OF OPEN TIBIA FRACTURES IN GERMANY, FRANCE, AND UK

    Nov 1, 2006, 00:00

  • PCN58 PRESCRIPTION MEDICATION COSTS TO PROSTATE CANCER PATIENTS- SURVEY RESPONSES COMPARED TO AN ADMINISTRATIVE REGISTER

    Nov 1, 2006, 00:00

  • PHP34 PHYSICIANS' ATTITUDES TO AND EXPERIENCE WITH INCREASED USE OF INDIVIDUAL REIMBURSEMENT VERSUS GENERAL REIMBURSEMENT OF NEW IMPORTANT PHARMACEUTICALS

    Nov 1, 2006, 00:00

  • PIH1 BUDGET IMPACT ANALYSIS OF AVODART (DUTASTERIDE) IN THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA (BPH) IN POLAND

    Nov 1, 2006, 00:00

  • PMH38 A MODEL TO ASSESS THE COST-EFFECTIVENESS OF NEW TREATMENTS FOR DEPRESSION

    Nov 1, 2006, 00:00

  • ES5 RIMONABANT FOR THE TREATMENT OF OVERWEIGHT AND OBESE INDIVIDUALS AT INCREASED CARDIOMETABOLIC RISK-AN ECONOMIC EVALUATION USING DISCRETE EVENT SIMULATION

    Nov 1, 2006, 00:00

  • PRS5 COSTS OF COPD EXACERBATIONS IN POLAND (RESULTS OF THE PILOT STUDY)

    Nov 1, 2006, 00:00

  • PMH1 COST-EFFECTIVENESS OF CLINICALLY PROVEN TREATMENT STRATEGIES FOR ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD)- IMPACT OF COEXISTING CONDITIONS

    Nov 1, 2006, 00:00

  • PMC10 ESTIMATING UTILITY VALUES FOR HEALTH STATUS USING THE SPANISH VERSION OF THE SF-36. IS IT WORTHY TO CALCULATE WEIGHT VALUES FOR UTILITY MEASURES?

    Nov 1, 2006, 00:00

  • PDB8 THE IMPACT OF IMPROVED BETA-CELL FUNCTION ON MODELLING THE COST-EFFECTIVENESS OF ROSIGLITAZONE IN THE MANAGEMENT OF TYPE 2 DIABETES IN SPAIN

    Nov 1, 2006, 00:00

  • PIH22 LINGUISTIC VALIDATION OF THE MENSTRUAL DISTRESS QUESTIONNAIRE (MDQ) IN AN INTERNATIONAL STUDY FOR A NEW COMBINED ORAL CONTRACEPTIVE PILL

    Nov 1, 2006, 00:00

  • PCN32 COST-MINIMIZATION ANALYSIS OF ORAL VS. IV FLUDARABINE FOR THE TREATMENT OF B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA (B-CLL) IN BRAZIL

    Nov 1, 2006, 00:00

  • Impact of Rofecoxib Withdrawal on Cyclooxygenase-2 Utilization among Patients with and without Cardiovascular Risk

    Nov 1, 2006, 00:00

  • PCV11 CLINICAL EFFECTIVENESS OF BETALOC ZOC COMPARED TO METOPROLOL TARTRATE OR CARVEDILOL IN HYPERTENSION TREATMENT

    Nov 1, 2006, 00:00

  • PGI10 COST-EFFECTIVENESS OF ESOMEPRAZOLE VERSUS GENERIC OMEPRAZOLE IN THE ACUTE TREATMENT OF REFLUX ESOPHAGITIS IN GERMANY

    Nov 1, 2006, 00:00

  • PHP18 PRICES OF GENERIC DRUGS IN FINLAND VS. EUROPE

    Nov 1, 2006, 00:00

  • PCN51 PHYSICIAN AND PATIENT CHARACTERISTICS ASSOCIATED WITH OUTPATIENT BREAST CANCER SCREENING RECOMMENDATIONS-ANALYSIS OF US OUTPATIENT DATA 1996–2004

    Nov 1, 2006, 00:00

  • DISCLOSURE INFORMATION

    Nov 1, 2006, 00:00

  • PCN43 COST-EFFECTIVENESS OF CETUXIMAB (ERBITUX®) IN COMBINATION WITH RADIOTHERAPY VERSUS RADIOTHERAPY ALONE IN THE TREATMENT OF LOCALLY ADVANCED HEAD AND NECK CANCER IN FRANCE

    Nov 1, 2006, 00:00

  • PEY21 IMPACT OF BILATERAL NEOVASCULAR AGE-RELATED MACULAR DEGENERATION AND RELATED VISUAL IMPAIRMENT ON PATIENTS' QUALITY OF LIFE AND FUNCTIONING- A SURVEY OF FIVE COUNTRIES

    Nov 1, 2006, 00:00

  • PDB45 EXPERIENCE OF HYPOGLYCEMIA IS SIGNIFICANTLY ASSOCIATED WITH LOWER QUALITY OF LIFE (EUROQOL) IN DIABETIC PATIENTS TREATED WITH METFORMIN (MF) IN COMBINATION WITH A SULPHONYLUREA (SU) IN FRANCE

    Nov 1, 2006, 00:00

  • PND12 A LITERATURE REVIEW OF PATIENT-REPORTED OUTOMES (PROS), NEUROPSYCHOLOGICAL AND COGNITIVE INSTRUMENTS IN PARKINSON'S DISEASE

    Nov 1, 2006, 00:00

  • PDB43 EFFECT OF INSULIN GLARGINE AND NPH ON QUALITY OF LIFE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS

    Nov 1, 2006, 00:00

  • PUK12 DECISION MODEL OF RESOURCE (TIME) SAVINGS GENERATED BY EXTENDED DOSING OF ERYTHROPOIESIS STIMULATING PROTEIN (ESP) FOR THE TREATMENT OF ANEMIA IN CHRONIC KIDNEY DISEASE (CKD) PATIENTS

    Nov 1, 2006, 00:00

  • PCN37 COMPARING MANAGEMENT PATTERNS AND ASSOCIATED COSTS FOR WOMEN WITH ABNORMAL CERVICAL CYTOLOGY IN 5 DIFFERENT COUNTRIES

    Nov 1, 2006, 00:00

  • PDB25 COST OF INPATIENT AND OUTPATIENT CARE OF SWEDISH PATIENTS WITH DIABETES MELLITUS

    Nov 1, 2006, 00:00

  • MC5 HUMANISTIC BURDEN AND HEALTH RESOURCE UTILIZATION AMONG NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (AMD) PATIENTS- RESULTS FOR GERMANY FROM A MULTI-COUNTRY CROSSSECTIONAL STUDY

    Nov 1, 2006, 00:00

  • PEY3 COMPARING EFFICACY OF PROSTAGLANDIN ANALOGUES FOR CONTROLLING INTRA-OCULAR PRESSURE (IOP)- RESULTS OF A META-ANALYSIS

    Nov 1, 2006, 00:00

  • PIH2 HEALTH ECONOMIC CONSEQUENCES OF THE CHOICE OF FOLLICLE STIMULATING HORMONE ALTERNATIVES IN IVF TREATMENT

    Nov 1, 2006, 00:00

  • POS3 KAPLAN-MEIER SURVIVAL ANALYSIS OF PATIENTS WITH MEDIAL AND LATERAL FEMORAL NECK FRACTURE OVER 60

    Nov 1, 2006, 00:00

  • PMH22 REHOSPITALIZATION RATES IN SCHIZOPHRENIA- COMPREHENSIVE LITERATURE REVIEW

    Nov 1, 2006, 00:00

  • PUK25 LINGUISTIC VALIDATION OF THE PATIENT PERCEPTION OF BLADDER CONDITION QUESTIONNAIRE (PPBC) IN 10 LANGUAGES

    Nov 1, 2006, 00:00

  • PUK2 LINKING CNI REGIMEN ADHERENCE TO HOSPITAL DAYS AND HEALTH CARE COSTS

    Nov 1, 2006, 00:00

  • PIH6 ECONOMIC EVALUATION OF CARBETOCINE FOR THE PREVENTION OF UTERINE ATONY IN PATIENTS WITH RISK FACTORS IN MEXICO

    Nov 1, 2006, 00:00

  • PCN7 IMPACT OF CHANGES IN THE FINANCING OF THE HEALTH SERVICES ON COSTS STRUCTURE ON THE EXAMPLE OF CHEMOTHERAPY OF ADVANCED OVARIAN CANCER

    Nov 1, 2006, 00:00

  • PCN63 ADVANCED CUTANEOUS MALIGNANT MELANOMA- SYSTEMATIC REVIEW OF PHARMACOECONOMIC AND QUALITY OF LIFE STUDIES

    Nov 1, 2006, 00:00

  • PIN13 ECONOMIC EVALUATION OF EARLY MONOTHERAPY WITH INTERFERON VERSUS DELAYED COMBINATION THERAPY WITH INTERFERON AND RIBAVIRIN IN PATIENTS WITH ACUTE HEPATITIS C

    Nov 1, 2006, 00:00

  • PIN17 THE COST-EFFECTIVENESS OF A MENINGOCOCCAL SEROGROUP C CONJUGATE VACCINE IN GERMANY

    Nov 1, 2006, 00:00

  • PST1 BUDGETARY IMPACT ANALYSIS OF RECOMBINANT ACTIVATED FACTOR VII IN THE TREATMENT OF INTRACEREBRAL HEMORRHAGE- A US HEALTH PLAN PERSPECTIVE

    Nov 1, 2006, 00:00

  • PND1 META-ANALYSIS OF THE EFFICACY AND TOLERABILITY OF PRAMIPEXOLE AND ROPINIROLE IN RESTLESS LEGS SYNDROME (RLS)

    Nov 1, 2006, 00:00

  • Too Much Ado about Propensity Score Models? Comparing Methods of Propensity Score Matching

    Nov 1, 2006, 00:00

  • PDB49 TREATMENT SATISFACTION WITH INSULIN GLARGINE AND INSULIN GLULISINE IN DIABETES MELLITUS-EVALUATED IN AN OBSERVATIONAL STUDY IN GERMANY

    Nov 1, 2006, 00:00

  • MC7 TRANSLATION AND VALIDATION OF NEW LANGUAGE VERSIONS OF THE ANKYLOSING SPONDYLITIS QUALITY OF LIFE (ASQOL) QUESTIONNAIRE

    Nov 1, 2006, 00:00

  • GI1 COST OF FUNCTIONAL DYSPEPSIA-RESULTS FROM A LARGE US EMPLOYER DATABASE

    Nov 1, 2006, 00:00

  • PMH8 BUDGET IMPACT MODEL FOR DETERMINING THE COSTS OF INTRODUCING ZIPRASIDONE FOR THE MANAGEMENT OF ACUTE BIPOLAR MANIA IN SPAIN

    Nov 1, 2006, 00:00

  • PIN31 HEALTH RELATED QUALITY OF LIFE IN CHRONIC HEPATITIS B PATIENTS

    Nov 1, 2006, 00:00

  • HP3 THE ROLE OF GENERAL PRACTITIONERS IN THE INITIAL MANAGEMENT OF WOMEN WITH URINARY INCONTINENCE IN FRANCE, GERMANY, SPAIN AND THE UK

    Nov 1, 2006, 00:00

  • PUK14 A COST-UTILITY ANALYSIS IN A UK SETTING OF CINACALCET FOR SECONDARY HYPERPARATHYROIDISM IN END STAGE RENAL DISEASE

    Nov 1, 2006, 00:00

  • ES3 PROCESS OPTIMIZATION IN A 10-BED INTENSIVE CARE UNIT (ICU) IN GERMANY- IMPACT ON CASE-RELATED TREATMENT COSTS

    Nov 1, 2006, 00:00

  • PHP27 THE ANALYSIS OF TEMPORARY WORK DISABILITY FOR THE PERIOD OF OVER 30 DAYS IN THE REPUBLIC OF SERBIA

    Nov 1, 2006, 00:00

  • PHP32 PATIENT SATISFACTION WITH THE PHARMACY FIRST MINOR AILMENTS SCHEME

    Nov 1, 2006, 00:00

  • PHP11 DOSE DISPENSED MEDICINE AND ASSOCIATED MEDICINE AND HEALTH CARE COST

    Nov 1, 2006, 00:00

  • PCV82 VALIDATION OF A MODEL TO PREDICT LIFETIME CLINICAL AND ECONOMIC BENEFIT OF RAISING HDL-C IN STATINTREATED PATIENTS WITH PERSISTENTLY LOW HDL-C

    Nov 1, 2006, 00:00

  • ES4 SYSTEMATIC REVIEW OF BUDGET IMPACT ANALYSES

    Nov 1, 2006, 00:00

  • PCV22 COST IMPACT OF DIAGNOSTIC IMAGING FOR LOWER EXTREMITY PERIPHERAL VASCULAR DISEASE (PVD)

    Nov 1, 2006, 00:00

  • PMH42 QUALITY OF LIFE IN PATIENTS WITH BIPOLAR DISORDER IN 5 EUROPEAN COUNTRIES

    Nov 1, 2006, 00:00

  • POS13 THE ESTIMATION OF COST–EFFECTIVENESS THRESHOLDS PRIOR TO THE START OF LARGE CLINICAL STUDIES

    Nov 1, 2006, 00:00

  • PUK17 USE OF SIMULATION TO CAPTURE THE MULTIFACTORIAL ASPECTS OF RENAL DISEASE

    Nov 1, 2006, 00:00

  • PHP14 STAKEHOLDERS' PERSPECTIVES ON IMPROVING ACCESS TO PRIMARY CARE

    Nov 1, 2006, 00:00

  • PMH33 STRUCTURAL EQUATION MODELLING OF SCHIZOPHRENIA EARLY RETIREMENT IN GERMANY

    Nov 1, 2006, 00:00

  • PIH21 INFLUENCE OF CONCOMITANT DISEASES ON THE CLINICAL RESPONSE TO TREATMENT FOR ERECTILE DYSFUNCTION

    Nov 1, 2006, 00:00

  • PIN10 COST-EFFECTIVENESS OF PEGINTERFERON ALFA-2A (40KD) FOR THE TREATMENT OF CHRONIC HEPATITIS B IN ITALY

    Nov 1, 2006, 00:00

  • PDB48 MANAGEMENT AND TREATMENT ADHERENCE IN TYPE 2 DIABETIC PATIENTS IN SPAIN

    Nov 1, 2006, 00:00

  • OA3 HOW DO PRESCRIBERS ACT WHEN A PRODUCT IS WITHDRAWN FROM THE MARKET? FIRST LESSONS FROM THE COX-2 INHIBITORS PATIENTS POST ROFECOXIB STUDY (CIPRES)

    Nov 1, 2006, 00:00

  • PHP5 THE PHARMACEUTICAL INDUSTRY PERSPECTIVE ON PHARMACOECONOMICS IN SAUDI ARABIA

    Nov 1, 2006, 00:00

  • PCV43 COST ANALYSIS OF TREATMENT WITH NESIRITIDE FOR ACUTE DECOMPENSATED HEART FAILURE IN A BRAZILIAN SETTING

    Nov 1, 2006, 00:00

  • CN3 PHARMACOECONOMIC (PE) ANALYSIS OF THE TREATMENT OF NON-SMALL CELL LUNG CANCER (NSCLC) IN THE NETHERLANDS DEMONSTRATES THAT ERLOTINIB DOMINATES DOCETAXEL AND IS COST-EFFECTIVE OVER BEST SUPPORTIVE CARE (BSC) WITHOUT NEED FOR PATIENT STRA ...

    Nov 1, 2006, 00:00

  • PRS17 VALIDATION OF THE COPD SEVERITY SCORE FOR USE IN THE SPANISH PRIMARY HEALTH CARE SYSTEM, THE NEREA STUDY- PRELIMINARY RESULTS

    Nov 1, 2006, 00:00

  • PMH29 ACUTE HOSPITALIZATION IN THE ELDERLY-RELATIONSHIP WITH PSYCHIATRIC MORBIDITY AND SOCIAL EQUITY IN HEALTH CARE ACESS IN SINGAPORE

    Nov 1, 2006, 00:00

  • PUK4 AN ECONOMIC EVALUATION OF DE NOVO RENAL TRANSPLANT RECIPIENTS USING BRANDED (B-CSA) VS. NON-BRANDED CYCLOSPORINE MODIFIED (NB-CSA)

    Nov 1, 2006, 00:00

  • PDB13 THE RELATIVE COST EFFECTIVENESS OF INSULIN GLARGINE VERSUS NPH INSULIN IN THE UK IN PEOPLE WITH TYPE 2 DIABETES

    Nov 1, 2006, 00:00

  • PMH24 ASSESSMENT OF RESOURCE UTILISATION IN ADULTS DIAGNOSED WITH DEPRESSION IN THE UK-A GPRD-BASED STUDY

    Nov 1, 2006, 00:00

  • PPN4 ECONOMIC EVALUATION COMPARING BMP-2 (INDUCTOSTM) VERSUS CURRENT TREATMENT IN CHRONIC LOWER BACK PAIN IN THE SPANISH SETTING

    Nov 1, 2006, 00:00

  • PMH18 DIRECT COST OF DEPRESSION–ANALYSIS OF A GERMAN CLAIMS DATABASE

    Nov 1, 2006, 00:00

  • PCV49 COST-UTILITY ANALYSIS USING A MARKOV MODEL TO COMPARE PRESCRIPTION STATINS VERSUS POTENTIAL OVER THE COUNTER STATINS IN USA

    Nov 1, 2006, 00:00

  • PAA5 ECONOMIC EVALUATION OF A NEW AIRWAY INFLAMMATION MONITOR IN THE DIAGNOSIS AND MANAGEMENT OF ASTHMA IN GERMANY

    Nov 1, 2006, 00:00

  • PGI13 ECONOMIC EVALUATION OF THE ARTIFICIAL LIVER SUPPORT SYSTEM MARS IN PATIENTS WITH ACUTE-ONCHRONIC LIVER FAILURE-FINAL RESULTS OF A CLINICAL COHORT TRIAL

    Nov 1, 2006, 00:00

  • PDB44 EXPLORING DIFFERENCES IN PATIENT VERSUS PUBLIC PREFERENCES IN HEALTH UTILITIES-A QUALITATIVE STUDY

    Nov 1, 2006, 00:00

  • PCN8 RISE OF HEALTH RESOURCE UTILIZATION AND COSTS FOR SEQUENTIAL DOCETAXEL IN NODE-POSITIVE PRIMARY BREAST CANCER IN GERMAN HOSPITALS

    Nov 1, 2006, 00:00

  • PHP6 ESTIMATION AND COMPARISON OF OSTOMY APPLIANCE COSTS WITH REIMBURSEMENT TARIFFS IN BELGIUM

    Nov 1, 2006, 00:00

  • PCV65 ECONOMIC APPRAISAL OF THE ANGIOPLASTY PROCEDURES PERFORMED IN 2004 IN A HIGH-VOLUME DIAGNOSTIC AND SURGICAL CARDIOLOGY UNIT

    Nov 1, 2006, 00:00

  • PHP35 TELEMEDICINE IN THE U.S. MEDICARE PROGRAM- 2007 REIMBURSEMENT IMPLICATIONS

    Nov 1, 2006, 00:00

  • PEY25 HEALTH-RELATED QUALITY-OF-LIFE AND UTILITY IN DUTCH GLAUCOMA PATIENTS

    Nov 1, 2006, 00:00

  • PIH3 VACCINATION WITH RIX4414 IS COST-EFFECTIVE IN A BELGIAN SETTING

    Nov 1, 2006, 00:00

  • PMH5 A 3-MONTH ASSESSMENT OF TREATMENT PRESCRIBED TO PATIENTS WITH ADHD AND ITS IMPACT ON CLINICAL SEVERITY AND QOL OUTCOMES ACROSS 10 EUROPEAN COUNTRIES. RESULTS FROM ATTENTION DEFICIT/ HYPERACTIVITY DISODER OBSERVATIONAL RESEARCH IN EUROP ...

    Nov 1, 2006, 00:00

  • PCV37 COST-EFFECTIVENESS OF LONG-TERM TREATMENT OF HYPERTENSION WITH IRBESARTAN VS. LOSARTAN OR NO TREATMENT IN DENMARK

    Nov 1, 2006, 00:00

  • PMH47 MEASURING RELAPSE AFTER ADOLESCENT SUBSTANCE ABUSE TREATMENT- A PROPORTIONAL HAZARD APPROACH

    Nov 1, 2006, 00:00

  • PCN11 PHARMACOECONOMIC ANALYSES OF ERLOTINIB COMPARED WITH BEST SUPPORTIVE CARE (BSC) FOR THE TREATMENT OF RELAPSED NON-SMALL CELL LUNG CANCER (NSCLC) FROM THE CANADIAN PUBLIC HEALTH CARE PERSPECTIVE

    Nov 1, 2006, 00:00

  • PDB26 COST-EFFECTIVENESS OF ROSIGLITAZONE FOR TREATMENT OF TYPE 2 DIABETES IN PORTUGAL USING DIFFERENT METHODS TO MODEL CLINICAL EFFECTS

    Nov 1, 2006, 00:00

  • PSK8 CONVERGENT VALIDITY AND SENSITIVITY TO CHANGE OF THE GENERIC INSTRUMENT EQ-5D AND THE DISEASESPECIFIC DLQI IN ATOPIC DERMATITIS

    Nov 1, 2006, 00:00

  • PUK28 VALIDATION OF THE PELVIC ORGAN PROLAPSE/URINARY INCONTINENCE SEXUAL FUNCTION QUESTIONNAIRE IN ITALIAN WOMEN. THE GYNAEFLOW STUDY

    Nov 1, 2006, 00:00

  • PDB20 THERAPY CLASS CONVERSION IN PATIENTS WITH TYPE 2 DIABETES- ECONOMIC EVALUATION OF INSULIN DETEMIR AND NPH

    Nov 1, 2006, 00:00

  • ES2 DIRECT MEDICAL COSTS OF SOLID ORGAN TRANSPLANT IN BRITISH COLUMBIA, CANADA

    Nov 1, 2006, 00:00

  • PHP10 POTENTIAL IMPACT OF HOSPITAL DISCHARGE PRESCRIPTIONS ON COMMUNITY PRESCRIBING-AN IRISH PERSPECTIVE

    Nov 1, 2006, 00:00

  • PMH31 PREDICTORS FOR REHOSPITALIZATION IN PATIENTS WITH SCHIZOPHRENIA

    Nov 1, 2006, 00:00

  • PUK5 COSTS AND COST-EFFECTIVENESS OF EPOETIN IN PATIENTS WITH CHRONIC RENAL INSUFFICIENCY DURING THE PREDIALYSIS PERIOD IN POLAND

    Nov 1, 2006, 00:00

  • PHP21 ANALYSIS OF COST OF ILLNESS IN THE NETHERLANDS IN 2003- INTEGRATING NATIONAL AND INTERNATIONAL PERSPECTIVES ON HEALTH CARE COSTS

    Nov 1, 2006, 00:00

  • PMH20 TREATMENT PATHWAYS AND COST ASSESSMENT OF SCHIZOPHRENIA IN GREECE- A PRIMARY ANALYSIS

    Nov 1, 2006, 00:00

  • PUK27 RISK OF LEAKAGES IN DAILY ACTIVITIES, RE-WORKING THE CONCEPTUAL FRAMEWORK

    Nov 1, 2006, 00:00

  • PHP13 BENEFIT INCIDENCE ANALYSIS BEFORE AND AFTER UNIVERSAL COVERAGE IN THAILAND

    Nov 1, 2006, 00:00

  • POB4 USING CLAIMS DATA TO UNDERSTAND THE COSTS OF DIFFERENT HEALTH STATES FOR PATIENTS WITH CARDIOMETABOLIC RISK

    Nov 1, 2006, 00:00

  • PCV75 DERIVING COST INPUT VALUES FOR USE IN A MARKOV MODEL FOR EXPLORING THE CLINICAL CONSEQUENCES OF RIMONABANT IN ADDITION TO DIET AND EXERCISE IN OVERWEIGHT OR OBESE SUBJECTS

    Nov 1, 2006, 00:00

  • PIN8 COST-EFFECTIVENESS OF INTERVENTIONS ENSURING BLOOD TRANSFUSION SAFETY IN AFRICA

    Nov 1, 2006, 00:00

  • PR3 LOW ADHERENCE WITH GASTROPROTECTIVE AGENTS WHEN CO-PRESCRIBED WITH NSNSAIDS ASSOCIATED WITH INCREASING RISK OF GI-RELATED HOSPITALISATION

    Nov 1, 2006, 00:00

  • PCV67 PROJECTED COST SAVINGS TO THIRD PARTY PAYERS FOR THE YEAR FOLLOWING GENERIC SIMVASTATIN AVAILABILITY IN USA

    Nov 1, 2006, 00:00

  • PCV5 DRUG-ELUTING STENT USE IS ASSOCIATED WITH SIGNIFICANT IMPROVEMENTS IN LONG-TERM CLINICAL OUTCOMES

    Nov 1, 2006, 00:00

  • POS5 AN ECONOMIC EVALUATION OF ZOLEDRONIC ACID TREATMENT IN PAGET'S DISEASE OF BONE IN THE HUNGARIAN HEALTH CARE SETTING

    Nov 1, 2006, 00:00

  • PCV53 COST-UTILITY ANALYSIS OF EPROSARTAN COMPARED TO ENALAPRIL AND RAMIPRIL IN THE TREATMENT OF MODERATE TO SEVERE HYPERTENSION IN SWEDEN

    Nov 1, 2006, 00:00

  • PCV66 THE VALUE OF MYOCARDIAL PERFUSION SCINTIGRAPHY (MPS) IN CORONARY ARTERY DISEASE (CAD)-A REVIEW OF THE ECONOMIC LITERATURE SUBMITTED TO THE UK NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE (NICE)

    Nov 1, 2006, 00:00

  • PCN60 ASSESSMENT OF THE COMPUTATIONAL INTELLIGENCE BASED MODELS USEFULNESS FOR PHARMACOECONOMICS NEEDS

    Nov 1, 2006, 00:00

  • PND2 ESTIMATING THE BUDGET IMPACT OF LEVETIRACETAM AS ADJUNCTIVE THERAPY IN CHILDREN WITH REFRACTORY PARTIAL ONSET SEIZURE IN THE UK

    Nov 1, 2006, 00:00

  • PMH4 ASSOCIATION BETWEEN CHANGES ON THE NEGATIVE SYMPTOM ASSESSMENT SCALE AND MEASUREES OF FUNCTIONAL OUTCOME IN SCHIZOPHRENIA

    Nov 1, 2006, 00:00

  • PHM8 INDIRECT COSTS OF BETA THALASSEMIA MAJOR- RESULTS FROM THE ITACA STUDY

    Nov 1, 2006, 00:00

  • PMH14 PHARMACOECONOMIC POSITIONING OF SERTINDOLE AMONG ANTIPSYCHOTICS IN THE MANAGEMENT OF SCHIZOPHRENIA- THE HUNGARIAN EXPERIENCE

    Nov 1, 2006, 00:00

  • PUK26 LINGUISTIC VALIDATION OF THE OVERACTIVE BLADDER SATISFACTION QUESTIONNAIRE (OAB-S) IN 13 LANGUAGES

    Nov 1, 2006, 00:00

  • POB8 THE IMPACT OF BODY WEIGHT ON UTILITY SCORES IN PATIENTS WITH TYPE 2 DIABETES

    Nov 1, 2006, 00:00

  • PCV51 ECONOMIC EVALUATION OF DIAGNOSTIC STRATEGIES IN PATIENTS WITH SUSPECTED CORONARY ARTERY DISEASE (CAD) IN THE UK

    Nov 1, 2006, 00:00

  • PCN26 PHARMACOECONOMIC ANALYSIS IN SPAIN OF THERAPY WITH ERLOTINIB, DOCETAXEL, PEMETREXED OR BEST SUPPORTIVE CARE IN PATIENTS WITH ADVANCED NONSMALL CELL LUNG CANCER WHO HAVE FAILED PREVIOUS CHEMOTHERAPY REGIMENS

    Nov 1, 2006, 00:00

  • PHP17 EFFICIENCY OF RHEUMATOLOGY HOSPITAL CARE- CHANGES IN THE AVERAGE LENGTH OF STAY IN RHEUMATOLOGY DEPARTMENTS IN HUNGARY

    Nov 1, 2006, 00:00

  • PRS6 CONSEQUENCES FOR DRG-IMPLEMENTATION IN GERMANY- EFFECT ON DIRECT COSTS OF IN-PATIENTS WITH COMMUNITY-ACQUIRED PNEUMONIA FROM HOSPITAL'S PERSPECTIVE

    Nov 1, 2006, 00:00

  • PMH36 SIX-MONTH FOLLOW-UP FROM THE ELECTRONICSCHIZOPHRENIA ADHERENCE TREATMENT REGISTRY (ESTAR) OF PATIENTS IN SPAIN WHO WERE INITIATED TO RISPERIDONE LONG-ACTING INJECTION (RLAI)

    Nov 1, 2006, 00:00

  • PIN27 ECONOMIC MODELLING TO DETERMINE THE COSTEFFECTIVENESS OF TREATMENT OF PATIENTS WITH HISTOLOGICALLY MILD CHRONIC HEPATITIS C WITH PEGYLATED INTERFERON ALPHA-2B PLUS RIBAVIRIN

    Nov 1, 2006, 00:00

  • PHP4 ASSESSING THERAPEUTIC IMPROVEMENT IN CANADA AND FRANCE- A COMPARISON OF PMPRB AND ASMR CLASSIFICATIONS

    Nov 1, 2006, 00:00

  • PIN25 LONG TERM EFFECT OF WARD PHARMACY CONTROLLED ADMINISTRATION OF ANTIBIOTICS ON ANTIMICROBIAL TREATMENT COSTS

    Nov 1, 2006, 00:00

  • PCN49 FACTORS INFLUENCING INEQUITABLE ACCESS TO RADIATION THERAPY- THE CASE STUDY OF CANCER PATIENTS IN THAILAND

    Nov 1, 2006, 00:00

  • ES8 TREATMENT COSTS OF DIFFERENT PHASES IN BREAST CANCER (BC) IN HUNGARY

    Nov 1, 2006, 00:00
  • «
  • 161
  • 162
  • 163 (current)
  • 164
  • 165
  • 166
  • 167
  • 168
  • 169
  • 170
  • »